Highlights Ribomic Inc.

Equities

4591

JP3974850004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-12 am EDT			5-day change	1st Jan Change
90 ^JPY	0.00%		-8.16%	-16.67%

Mar. 07	Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI
Feb. 20	Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	Feb. 13	CI
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	Jan. 17	MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	Jan. 17	MT
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement	Jan. 16	CI
RIBOMIC Phase I and II Data Published in the Eye	Dec. 05	CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 13	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024	23-08-10	CI
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	23-05-12	CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan	23-04-27	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	23-02-10	CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	23-02-10	CI
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%	22-12-26	MT
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China	22-12-23	CI
Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia Patients	22-11-28	CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-11	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-11-11	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-08-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ribomic Inc.

Equities

4591

JP3974850004

Highlights

Filters